Association of glycogen synthase kinase-3β with Parkinson's disease (Review)

Molecular Medicine Reports

Volumn 9, Issue 6, 2014, Pages 2043-2050

  Li, Da Wei ^a   Liu, Zhi Qiang ^b   Chen, Wei ^c   Yao, Min ^c   Li, Guang Ren ^c  

^a BEIHUA UNIVERSITY   (China)

^b THE FIRST HOSPITAL OF JILIN UNIVERSITY   (China)

^c CHINA JAPAN UNION HOSPITAL OF JILIN UNIVERSITY   (China)

Author keywords

Glycogen synthase kinase 3 ; Parkinson's disease; Regulation

Indexed keywords

ALPHA SYNUCLEIN; GLYCOGEN SYNTHASE KINASE 3BETA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MIXED LINEAGE KINASE 3; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (UBIQUINONE); STRESS ACTIVATED PROTEIN KINASE; TAU PROTEIN; BRACHYURY PROTEIN; FETOPROTEIN; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3 BETA; T BOX TRANSCRIPTION FACTOR;

APOPTOSIS; BRAIN NERVE CELL; CELL SURVIVAL; CYTOKINE RELEASE; DEGENERATIVE DISEASE; DISEASE ASSOCIATION; DOPAMINERGIC NERVE CELL; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; GENE EXPRESSION; HUMAN; LEWY BODY; NERVOUS SYSTEM INFLAMMATION; NEUROPATHOLOGY; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PROTEIN AGGREGATION; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; SUBSTANTIA NIGRA; ANIMAL; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETICS; INFLAMMATION; METABOLISM; MITOCHONDRION;

ALPHA-SYNUCLEIN; ANIMALS; APOPTOSIS; ELECTRON TRANSPORT COMPLEX I; FETAL PROTEINS; GENE EXPRESSION REGULATION; GLYCOGEN SYNTHASE KINASE 3; HUMANS; INFLAMMATION; MITOCHONDRIA; PARKINSON DISEASE; REACTIVE OXYGEN SPECIES; SIGNAL TRANSDUCTION; T-BOX DOMAIN PROTEINS;

EID: 84899670837     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2014.2080     Document Type: Review

References (137)

1. Forno LS: Neuropathology of Parkinson's disease. J Neuropathol Exp Neurol 55: 259-272, 1996.
2. McNaught KS and Olanow CW: Protein aggregation in the pathogenesis of familial and sporadic Parkinson's disease. Neurobiol Aging 27: 530-545, 2006. (Pubitemid 43290522)
3. Martinez-Vicente M, Talloczy Z, Kaushik S, et al : Dopamine-modified alpha-synuclein blocks chaperone-mediated autophagy. J Clin Invest 118: 777-788, 2008.
4. Keeney PM, Xie J, Capaldi RA and Bennett JP Jr: Parkinson's disease brain mitochondrial complex I has oxidatively damaged subunits and is functionally impaired and misassembled. J Neurosci 26: 5256-5264, 2006. (Pubitemid 44315308)
5. Li DW, Li GR, Lu Y, et al: alpha-lipoic acid protects dopaminergic neurons against MPP+-induced apoptosis by attenuating reactive oxygen species formation. Int J Mol Med 32: 108-114, 2013.
6. 2+)-dependent apoptosis and necrosis. Cell Calcium 50: 222-233, 2011.
7. Parker WD Jr, Boyson SJ and Parks JK: Abnormalities of the electron transport chain in idiopathic Parkinson's disease. Ann Neurol 26: 719-723, 1989. (Pubitemid 20011004)
8. Schapira AH, Cooper JM, Dexter D, Jenner P, Clark JB and Marsden CD: Mitochondrial complex I deficiency in Parkinson's disease. Lancet 1: 1269, 1989. (Pubitemid 19140359)
9. Betarbet R, Sherer TB, MacKenzie G, Garcia-Osuna M, Panov AV and Greenamyre JT: Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat Neurosci 3: 1301-1306, 2000.
10. Cannon JR, Tapias V, Na HM, Honick AS, Drolet RE and Greenamyre JT: A highly reproducible rotenone model of Parkinson's disease. Neurobiol Dis 34: 279-290, 2009.
11. Hantraye P, Brouillet E, Ferrante R, et al: Inhibition of neuronal nitric oxide synthase prevents MPTP-induced parkinsonism in baboons. Nat Med 2: 1017-1021, 1996. (Pubitemid 26306841)
12. Shang T, Kotamraju S, Kalivendi SV, Hillard CJ and Kalyanaraman B: 1-Methyl-4-phenylpyridinium-induced apoptosis in cerebellar granule neurons is mediated by transferrin receptor iron-dependent depletion of tetrahydrobiopterin and neuronal nitric-oxide synthase-derived superoxide. J Biol Chem 279: 19099-19112, 2004. (Pubitemid 38623341)
13. Hartley A, Stone JM, Heron C, Cooper JM and Schapira AH: Complex I inhibitors induce dose-dependent apoptosis in PC12 cells: relevance to Parkinson's disease. J Neurochem 63: 1987-1990, 1994. (Pubitemid 24326248)
14. Kreutzberg GW: Microglia: a sensor for pathological events in the CNS. Trends Neurosci 19: 312-318, 1996.
15. Monahan AJ, Warren M and Carvey PM: Neuroinflammation and peripheral immune infiltration in Parkinson's disease: an autoimmune hypothesis. Cell Transplant 17: 363-372, 2008. (Pubitemid 351717339)
16. Hirsch EC and Hunot S: Neuroinflammation in Parkinson's disease: a target for neuroprotection? Lancet Neurol 8: 382-397, 2009.
17. Gao HM, Zhou H, Zhang F, Wilson BC, Kam W and Hong JS: HMGB1 acts on microglia Mac1 to mediate chronic neuroinflammation that drives progressive neurodegeneration. J Neurosci 31: 1081-1092, 2011.
18. McGeer PL, Schwab C, Parent A and Doudet D: Presence of reactive microglia in monkey substantia nigra years after 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine administration. Ann Neurol 54: 599-604, 2003. (Pubitemid 37346066)
19. Block ML, Zecca L and Hong JS: Microglia-mediated neurotoxicity: uncovering the molecular mechanisms. Nat Rev Neurosci 8: 57-69, 2007. (Pubitemid 46011999)
20. Gao HM, Liu B, Zhang W and Hong JS: Novel anti-inflammatory therapy for Parkinson's disease. Trends Pharmacol Sci 24: 395-401, 2003. (Pubitemid 36952555)
21. Wu DC, Teismann P, Tieu K, et al: NADPH oxidase mediates oxidative stress in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease. Proc Natl Acad Sci USA 100: 6145-6150, 2003. (Pubitemid 36576945)
22. Zhang F, Qian L, Flood PM, Shi JS, Hong JS and Gao HM: Inhibition of IkappaB kinase-beta protects dopamine neurons against lipopolysaccharide-induced neurotoxicity. J Pharmacol Exp Ther 333: 822-833, 2010.
23. Wang W, Yang Y, Ying C, et al: Inhibition of glycogen synthase kinase-3beta protects dopaminergic neurons from MPTP toxicity. Neuropharmacology 52: 1678-1684, 2007. (Pubitemid 46843143)
24. King TD, Bijur GN and Jope RS: Caspase-3 activation induced by inhibition of mitochondrial complex I is facilitated by glycogen synthase kinase-3beta and attenuated by lithium. Brain Res 919: 106-114, 2001. (Pubitemid 33016593)
25. Woodgett JR: Molecular cloning and expression of glycogen synthase kinase-3/factor A. EMBO J 9: 2431-2438, 1990.
26. Parker PJ, Embi N, Caudwell FB and Cohen P: Glycogen synthase from rabbit skeletal muscle. State of phosphorylation of the seven phosphoserine residues in vivo in the presence and absence of adrenaline. Eur J Biochem 124: 47-55, 1982. (Pubitemid 12094715)
27. Jope RS and Johnson GV: The glamour and gloom of glycogen synthase kinase-3. Trends Biochem Sci 29: 95-102, 2004. (Pubitemid 38186580)
28. Kockeritz L, Doble B, Patel S and Woodgett JR: Glycogen synthase kinase-3 - an overview of an over-achieving protein kinase. Curr Drug Targets 7: 1377-1388, 2006. (Pubitemid 44718298)
29. Miura T, Tanno M and Sato T: Mitochondrial kinase signalling pathways in myocardial protection from ischaemia/reperfusion-induced necrosis. Cardiovasc Res 88: 7-15, 2010.
30. Medina M, Garrido JJ and Wandosell FG: Modulation of GSK-3 as a Therapeutic Strategy on Tau Pathologies. Front Mol Neurosci 4: 24, 2011.
31. King MR, Anderson NJ, Guernsey LS and Jolivalt CG: Glycogen synthase kinase-3 inhibition prevents learning deficits in diabetic mice. J Neurosci Res 91: 506-514, 2013.
32. Zheng H, Li W, Wang Y, et al: Glycogen synthase kinase-3 beta regulates Snail and beta-catenin expression during Fas-induced epithelial-mesenchymal transition in gastrointestinal cancer. Eur J Cancer 2013.
33. Dajani R, Fraser E, Roe SM, et al: Crystal structure of glycogen synthase kinase 3 beta: structural basis for phosphate-primed substrate specificity and autoinhibition. Cell 105: 721-732, 2001. (Pubitemid 32635102)
34. Xavier IJ, Mercier PA, McLoughlin CM, Ali A, Woodgett JR and Ovsenek N: Glycogen synthase kinase 3beta negatively regulates both DNA-binding and transcriptional activities of heat shock factor 1. J Biol Chem 275: 29147-29152, 2000.
35. Bijur GN and Jope RS: Proapoptotic stimuli induce nuclear accumulation of glycogen synthase kinase-3 beta. J Biol Chem 276: 37436-37442, 2001.
36. Bijur GN and Jope RS: Glycogen synthase kinase-3 beta is highly activated in nuclei and mitochondria. Neuroreport 14: 2415-2419, 2003.
37. Hoshi M, Sato M, Kondo S, et al: Different localization of tau protein kinase I/glycogen synthase kinase-3 beta from glycogen synthase kinase-3 alpha in cerebellum mitochondria. J Biochem 118: 683-685, 1995.
38. Senatorov VV, Ren M, Kanai H, Wei H and Chuang DM: Short-term lithium treatment promotes neuronal survival and proliferation in rat striatum infused with quinolinic acid, an excitotoxic model of Huntington's disease. Mol Psychiatry 9: 371-385, 2004. (Pubitemid 38534698)
39. Bijur GN, De Sarno P and Jope RS: Glycogen synthase kinase-3beta facilitates staurosporine- and heat shock-induced apoptosis. Protection by lithium. J Biol Chem 275: 7583-7590, 2000. (Pubitemid 30159657)
40. Alvarez AR, Godoy JA, Mullendorff K, Olivares GH, Bronfman M and Inestrosa NC: Wnt-3a overcomes beta-amyloid toxicity in rat hippocampal neurons. Exp Cell Res 297: 186-196, 2004. (Pubitemid 38759572)
41. Wu Y, Shang Y, Sun S, Liang H and Liu R: Erythropoietin prevents PC12 cells from 1-methyl-4-phenylpyridinium ion-induced apoptosis via the Akt/GSK-3beta/caspase-3 mediated signaling pathway. Apoptosis 12: 1365-1375, 2007. (Pubitemid 46988273)
42. Petit-Paitel A, Brau F, Cazareth J and Chabry J: Involvment of cytosolic and mitochondrial GSK-3beta in mitochondrial dysfunction and neuronal cell death of MPTP/MPP-treated neurons. PLoS One 4: e5491, 2009.
43. King TD, Clodfelder-Miller B, Barksdale KA and Bijur GN: Unregulated mitochondrial GSK3beta activity results in NADH: ubiquinone oxidoreductase deficiency. Neurotox Res 14: 367-382, 2008.
44. Huang WC, Lin YS, Wang CY, et al: Glycogen synthase kinase-3 negatively regulates anti-inflammatory interleukin-10 for lipopolysaccharide-induced iNOS/NO biosynthesis and RANTES production in microglial cells. Immunology 128: e275-e286, 2009.
45. Yuskaitis CJ and Jope RS: Glycogen synthase kinase-3 regulates microglial migration, inflammation, and inflammation-induced neurotoxicity. Cell Signal 21: 264-273, 2009.
46. 2+ signaling. Am J Physiol Cell Physiol 291: C1082-C1088, 2006.
47. Grivennikova VG and Vinogradov AD: Generation of superoxide by the mitochondrial Complex I. Biochim Biophys Acta 1757: 553-561, 2006. (Pubitemid 43993849)
48. Abou-Sleiman PM, Muqit MM and Wood NW: Expanding insights of mitochondrial dysfunction in Parkinson's disease. Nat Rev Neurosci 7: 207-219, 2006. (Pubitemid 43292466)
49. Langston JW, Ballard P, Tetrud JW and Irwin I: Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science 219: 979-980, 1983. (Pubitemid 13189531)
50. Chiba K, Trevor A and Castagnoli N Jr: Metabolism of the neurotoxic tertiary amine, MPTP, by brain monoamine oxidase. Biochem Biophys Res Commun 120: 574-578, 1984. (Pubitemid 14101750)
51. Javitch JA, D'Amato RJ, Strittmatter SM and Snyder SH: Parkinsonism-inducing neurotoxin, N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: uptake of the metabolite N-methyl-4-phenylpyridine by dopamine neurons explains selective toxicity. Proc Natl Acad Sci USA 82: 2173-2177, 1985. (Pubitemid 15056491)
52. Bindoff LA, Birch-Machin M, Cartlidge NE, Parker WD Jr and Turnbull DM: Mitochondrial function in Parkinson's disease. Lancet 2: 49, 1989. (Pubitemid 19158192)
53. Kussmaul L and Hirst J: The mechanism of superoxide production by NADH:ubiquinone oxidoreductase (complex I) from bovine heart mitochondria. Proc Natl Acad Sci USA 103: 7607-7612, 2006.
54. Sipos I, Tretter L and Adam-Vizi V: Quantitative relationship between inhibition of respiratory complexes and formation of reactive oxygen species in isolated nerve terminals. J Neurochem 84: 112-118, 2003. (Pubitemid 36182071)
55. Murphy MP: How mitochondria produce reactive oxygen species. Biochem J 417: 1-13, 2009.
56. Cassarino DS, Fall CP, Swerdlow RH, et al: Elevated reactive oxygen species and antioxidant enzyme activities in animal and cellular models of Parkinson's disease. Biochim Biophys Acta 1362: 77-86, 1997. (Pubitemid 28027114)
57. Pastorino JG, Hoek JB and Shulga N: Activation of glycogen synthase kinase 3beta disrupts the binding of hexokinase II to mitochondria by phosphorylating voltage-dependent anion channel and potentiates chemotherapy-induced cytotoxicity. Cancer Res 65: 10545-10554, 2005. (Pubitemid 41743749)
58. Watcharasit P, Bijur GN, Song L, Zhu J, Chen X and Jope RS: Glycogen synthase kinase-3beta (GSK3beta) binds to and promotes the actions of p53. J Biol Chem 278: 48872-48879, 2003.
59. Valerio A, Bertolotti P, Delbarba A, et al: Glycogen synthase kinase-3 inhibition reduces ischemic cerebral damage, restores impaired mitochondrial biogenesis and prevents ROS production. J Neurochem 116: 1148-1159, 2011.
60. Vila M and Przedborski S: Targeting programmed cell death in neurodegenerative diseases. Nat Rev Neurosci 4: 365-375, 2003. (Pubitemid 37280175)
61. Perier C, Tieu K, Guegan C, et al: Complex I deficiency primes Bax-dependent neuronal apoptosis through mitochondrial oxidative damage. Proc Natl Acad Sci USA 102: 19126-19131, 2005. (Pubitemid 43049577)
62. Roucou X and Martinou JC: Conformational change of Bax: a question of life or death. Cell Death Differ 8: 875-877, 2001. (Pubitemid 32782754)
63. Obame FN, Plin-Mercier C, Assaly R, et al: Cardioprotective effect of morphine and a blocker of glycogen synthase kinase 3 beta, SB216763 [3-(2,4-dichlorophenyl)-4(1-methyl-1H-indol-3-yl)-1H-pyrrole-2,5-dione], via inhibition of the mitochondrial permeability transition pore. J Pharmacol Exp Ther 326: 252-258, 2008. (Pubitemid 351872117)
64. Nishihara M, Miura T, Miki T, et al: Modulation of the mitochondrial permeability transition pore complex in GSK-3beta-mediated myocardial protection. J Mol Cell Cardiol 43: 564-570, 2007. (Pubitemid 47615050)
65. Feng J, Lucchinetti E, Ahuja P, Pasch T, Perriard JC and Zaugg M: Isoflurane postconditioning prevents opening of the mitochondrial permeability transition pore through inhibition of glycogen synthase kinase 3beta. Anesthesiology 103: 987-995, 2005. (Pubitemid 41552054)
66. Park SS, Zhao H, Mueller RA and Xu Z: Bradykinin prevents reperfusion injury by targeting mitochondrial permeability transition pore through glycogen synthase kinase 3beta. J Mol Cell Cardiol 40: 708-716, 2006.
67. Gomez L, Paillard M, Thibault H, Derumeaux G and Ovize M: Inhibition of GSK3beta by postconditioning is required to prevent opening of the mitochondrial permeability transition pore during reperfusion. Circulation 117: 2761-2768, 2008. (Pubitemid 351770456)
68. Zhou K, Zhang L, Xi J, Tian W and Xu Z: Ethanol prevents oxidant-induced mitochondrial permeability transition pore opening in cardiac cells. Alcohol Alcohol 44: 20-24, 2009.
69. Youdim MB and Arraf Z: Prevention of MPTP (N-methyl-4-phenyl-1,2,3,6- tetrahydropyridine) dopaminergic neurotoxicity in mice by chronic lithium: involvements of Bcl-2 and Bax. Neuropharmacology 46: 1130-1140, 2004. (Pubitemid 38529937)
70. Linseman DA, Butts BD, Precht TA, et al: Glycogen synthase kinase-3beta phosphorylates Bax and promotes its mitochondrial localization during neuronal apoptosis. J Neurosci 24: 9993-10002, 2004. (Pubitemid 39463581)
71. Maurer U, Charvet C, Wagman AS, Dejardin E and Green DR: Glycogen synthase kinase-3 regulates mitochondrial outer membrane permeabilization and apoptosis by destabilization of MCL-1. Mol Cell 21: 749-760, 2006. (Pubitemid 43376126)
72. Tsujimoto Y and Shimizu S: VDAC regulation by the Bcl-2 family of proteins. Cell Death Differ 7: 1174-1181, 2000. (Pubitemid 32042224)
73. Martinou JC and Green DR: Breaking the mitochondrial barrier. Nat Rev Mol Cell Biol 2: 63-67, 2001.
74. Armstrong JS: Mitochondrial membrane permeabilization: the sine qua non for cell death. Bioessays 28: 253-260, 2006.
75. Gollapudi S, McCormick MJ and Gupta S: Changes in mitochondrial membrane potential and mitochondrial mass occur independent of the activation of caspase-8 and caspase-3 during CD95-mediated apoptosis in peripheral blood T cells. Int J Oncol 22: 597-600, 2003.
76. Tan J, Zhuang L, Leong HS, Iyer NG, Liu ET and Yu Q: Pharmacologic modulation of glycogen synthase kinase-3beta promotes p53-dependent apoptosis through a direct Bax-mediated mitochondrial pathway in colorectal cancer cells. Cancer Res 65: 9012-9020, 2005. (Pubitemid 41377393)
77. Chen G, Zeng WZ, Yuan PX, et al: The mood-stabilizing agents lithium and valproate robustly increase the levels of the neuroprotective protein bcl-2 in the CNS. J Neurochem 72: 879-882, 1999. (Pubitemid 29055256)
78. Kaga S, Zhan L, Altaf E and Maulik N: Glycogen synthase kinase-3beta/beta-catenin promotes angiogenic and anti-apoptotic signaling through the induction of VEGF, Bcl-2 and survivin expression in rat ischemic preconditioned myocardium. J Mol Cell Cardiol 40: 138-147, 2006. (Pubitemid 43012125)
79. Chen RW and Chuang DM: Long term lithium treatment suppresses p53 and Bax expression but increases Bcl-2 expression. A prominent role in neuroprotection against excitotoxicity. J Biol Chem 274: 6039-6042, 1999.
80. Ohori K, Miura T, Tanno M, et al: Ser9 phosphorylation of mitochondrial GSK-3beta is a primary mechanism of cardiomyocyte protection by erythropoietin against oxidant-induced apoptosis. Am J Physiol Heart Circ Physiol 295: H2079-H2086, 2008.
81. Ge XH, Zhu GJ, Geng DQ, Zhang ZJ and Liu CF: Erythropoietin attenuates 6-hydroxydopamine-induced apoptosis via glycogen synthase kinase 3b-mediated mitochondrial translocation of Bax in PC12 cells. Neurol Sci 33: 1249-1256, 2012.
82. Ngok-Ngam P, Watcharasit P, Thiantanawat A and Satayavivad J: Pharmacological inhibition of GSK3 attenuates DNA damage-induced apoptosis via reduction of p53 mitochondrial translocation and Bax oligomerization in neuroblastoma SH-SY5Y cells. Cell Mol Biol Lett 18: 58-74, 2013.
83. Samii A, Nutt JG and Ransom BR: Parkinson's disease. Lancet 363: 1783-1793, 2004. (Pubitemid 38698383)
84. Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R and Goedert M: Alpha-synuclein in Lewy bodies. Nature 388: 839-840, 1997.
85. Singleton AB, Farrer M, Johnson J, et al: alpha-Synuclein locus triplication causes Parkinson's disease. Science 302: 841, 2003. (Pubitemid 37339619)
86. Liu D, Jin L, Wang H, et al: Silencing alpha-synuclein gene expression enhances tyrosine hydroxylase activity in MN9D cells. Neurochem Res 33: 1401-1409, 2008.
87. Baptista MJ, O'Farrell C, Daya S, et al: Co-ordinate transcriptional regulation of dopamine synthesis genes by alpha-synuclein in human neuroblastoma cell lines. J Neurochem 85: 957-968, 2003. (Pubitemid 36578627)
88. Perez RG, Waymire JC, Lin E, Liu JJ, Guo F and Zigmond MJ: A role for alpha-synuclein in the regulation of dopamine biosynthesis. J Neurosci 22: 3090-3099, 2002. (Pubitemid 35379198)
89. Yu S, Zuo X, Li Y, et al: Inhibition of tyrosine hydroxylase expression in alpha-synuclein-transfected dopaminergic neuronal cells. Neurosci Lett 367: 34-39, 2004. (Pubitemid 39078779)
90. Danzer KM, Haasen D, Karow AR, et al: Different species of alpha-synuclein oligomers induce calcium influx and seeding. J Neurosci 27: 9220-9232, 2007. (Pubitemid 47312071)
91. Periquet M, Fulga T, Myllykangas L, Schlossmacher MG and Feany MB: Aggregated alpha-synuclein mediates dopaminergic neurotoxicity in vivo. J Neurosci 27: 3338-3346, 2007. (Pubitemid 46474139)
92. Desplats P, Lee HJ, Bae EJ, et al: Inclusion formation and neuronal cell death through neuron-to-neuron transmission of alpha-synuclein. Proc Natl Acad Sci USA 106: 13010-13015, 2009.
93. Masliah E, Rockenstein E, Veinbergs I, et al: Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders. Science 287: 1265-1269, 2000. (Pubitemid 30112148)
94. Parihar MS, Parihar A, Fujita M, Hashimoto M and Ghafourifar P: Mitochondrial association of alpha-synuclein causes oxidative stress. Cell Mol Life Sci 65: 1272-1284, 2008.
95. Parihar MS, Parihar A, Fujita M, Hashimoto M and Ghafourifar P: Alpha-synuclein overexpression and aggregation exacerbates impairment of mitochondrial functions by augmenting oxidative stress in human neuroblastoma cells. Int J Biochem Cell Biol 41: 2015-2024, 2009.
96. Hsu LJ, Sagara Y, Arroyo A, et al: alpha-synuclein promotes mitochondrial deficit and oxidative stress. Am J Pathol 157: 401-410, 2000. (Pubitemid 30627559)
97. Feng LR, Federoff HJ, Vicini S and Maguire-Zeiss KA: Alpha-synuclein mediates alterations in membrane conductance: a potential role for alpha-synuclein oligomers in cell vulnerability. Eur J Neurosci 32: 10-17, 2010.
98. Lee EJ, Woo MS, Moon PG, et al: Alpha-synuclein activates microglia by inducing the expressions of matrix metalloproteinases and the subsequent activation of protease-activated receptor-1. J Immunol 185: 615-623, 2010.
99. Su X, Federoff HJ and Maguire-Zeiss KA: Mutant alpha-synuclein overexpression mediates early proinflammatory activity. Neurotox Res 16: 238-254, 2009.
100. Theodore S, Cao S, McLean PJ and Standaert DG: Targeted overexpression of human alpha-synuclein triggers microglial activation and an adaptive immune response in a mouse model of Parkinson disease. J Neuropathol Exp Neurol 67: 1149-1158, 2008.
101. Kozikowski AP, Gaisina IN, Petukhov PA, et al: Highly potent and specific GSK-3beta inhibitors that block tau phosphorylation and decrease alpha-synuclein protein expression in a cellular model of Parkinson's disease. ChemMedChem 1: 256-266, 2006. (Pubitemid 43700306)
102. Haggerty T, Credle J, Rodriguez O, et al: Hyperphosphorylated Tau in an alpha-synuclein-overexpressing transgenic model of Parkinson's disease. Eur J Neurosci 33: 1598-1610, 2011.
103. Wills J, Jones J, Haggerty T, Duka V, Joyce JN and Sidhu A: Elevated tauopathy and alpha-synuclein pathology in postmortem Parkinson's disease brains with and without dementia. Exp Neurol 225: 210-218, 2010.
104. Cho JH and Johnson GV: Glycogen synthase kinase 3 beta induces caspase-cleaved tau aggregation in situ. J Biol Chem 279: 54716-54723, 2004.
105. Peng JH, Zhang CE, Wei W, Hong XP, Pan XP and Wang JZ: Dehydroevodiamine attenuates tau hyperphosphorylation and spatial memory deficit induced by activation of glycogen synthase kinase-3 in rats. Neuropharmacology 52: 1521-1527, 2007. (Pubitemid 46695738)
106. Chun W and Johnson GV: Activation of glycogen synthase kinase 3beta promotes the intermolecular association of tau. The use of fluorescence resonance energy transfer microscopy. J Biol Chem 282: 23410-23417, 2007. (Pubitemid 47311920)
107. Greco SJ, Sarkar S, Casadesus G, et al: Leptin inhibits glycogen synthase kinase-3beta to prevent tau phosphorylation in neuronal cells. Neurosci Lett 455: 191-194, 2009.
108. Crouch PJ, Hung LW, Adlard PA, et al: Increasing Cu bioavailability inhibits Abeta oligomers and tau phosphorylation. Proc Natl Acad Sci USA 106: 381-386, 2009.
109. Engel T, Lucas JJ, Gomez-Ramos P, Moran MA, Avila J and Hernandez F: Cooexpression of FTDP-17 tau and GSK-3beta in transgenic mice induce tau polymerization and neurodegeneration. Neurobiol Aging 27: 1258-1268, 2006. (Pubitemid 44088576)
110. Engel T, Hernandez F, Avila J and Lucas JJ: Full reversal of Alzheimer's disease-like phenotype in a mouse model with conditional overexpression of glycogen synthase kinase-3. J Neurosci 26: 5083-5090, 2006. (Pubitemid 44315289)
111. Perez M, Hernandez F, Lim F, Diaz-Nido J and Avila J: Chronic lithium treatment decreases mutant tau protein aggregation in a transgenic mouse model. J Alzheimers Dis 5: 301-308, 2003. (Pubitemid 37411777)
112. Nakashima H, Ishihara T, Suguimoto P, et al: Chronic lithium treatment decreases tau lesions by promoting ubiquitination in a mouse model of tauopathies. Acta Neuropathol 110: 547-556, 2005. (Pubitemid 41763984)
113. Engel T, Goni-Oliver P, Lucas JJ, Avila J and Hernandez F: Chronic lithium administration to FTDP-17 tau and GSK-3beta overexpressing mice prevents tau hyperphosphorylation and neurofibrillary tangle formation, but pre-formed neurofibrillary tangles do not revert. J Neurochem 99: 1445-1455, 2006. (Pubitemid 44924224)
114. Gao HM and Hong JS: Why neurodegenerative diseases are progressive: uncontrolled inflammation drives disease progression. Trends Immunol 29: 357-365, 2008.
115. Kim SU and de Vellis J: Microglia in health and disease. J Neurosci Res 81: 302-313, 2005. (Pubitemid 41359284)
116. Mrak RE and Griffin WS: Glia and their cytokines in progression of neurodegeneration. Neurobiol Aging 26: 349-354, 2005. (Pubitemid 40082718)
117. McGeer PL and McGeer EG: Glial reactions in Parkinson's disease. Mov Disord 23: 474-483, 2008.
118. Ouchi Y, Yagi S, Yokokura M and Sakamoto M: Neuroinflammation in the living brain of Parkinson's disease. Parkinsonism Relat Disord 15 Suppl 3: S200-S204, 2009.
119. Hunot S, Dugas N, Faucheux B, et al: FcepsilonRII/CD23 is expressed in Parkinson's disease and induces, in vitro, production of nitric oxide and tumor necrosis factor-alpha in glial cells. J Neurosci 19: 3440-3447, 1999. (Pubitemid 29203124)
120. Mogi M, Harada M, Narabayashi H, Inagaki H, Minami M and Nagatsu T: Interleukin (IL)-1 beta, IL-2, IL-4, IL-6 and transforming growth factor-alpha levels are elevated in ventricular cerebrospinal fluid in juvenile parkinsonism and Parkinson's disease. Neurosci Lett 211: 13-16, 1996. (Pubitemid 26228016)
121. Koziorowski D, Tomasiuk R, Szlufik S and Friedman A: Inflammatory cytokines and NT-proCNP in Parkinson's disease patients. Cytokine 60: 762-766, 2012.
122. Przedborski S: Inflammation and Parkinson's disease pathogenesis. Mov Disord 25 Suppl 1: S55-S57, 2010.
123. Frankola KA, Greig NH, Luo W and Tweedie D: Targeting TNF-alpha to elucidate and ameliorate neuroinflammation in neurodegenerative diseases. CNS Neurol Disord Drug Targets 10: 391-403, 2011.
124. Qian L, Flood PM and Hong JS: Neuroinflammation is a key player in Parkinson's disease and a prime target for therapy. J Neural Transm 117: 971-979, 2010.
125. Lofrumento DD, Nicolardi G, Cianciulli A, et al : Neuroprotective effects of resveratrol in an MPTP mouse model of Parkinson's-like disease: Possible role of SOCS-1 in reducing pro-inflammatory responses. Innate Immun 2013.
126. Martin M, Rehani K, Jope RS and Michalek SM: Toll-like receptor-mediated cytokine production is differentially regulated by glycogen synthase kinase 3. Nat Immunol 6: 777-784, 2005. (Pubitemid 43090463)
127. Jope RS, Yuskaitis CJ and Beurel E: Glycogen synthase kinase-3 (GSK3): inflammation, diseases, and therapeutics. Neurochem Res 32: 577-595, 2007. (Pubitemid 46481289)
128. Beurel E and Jope RS: Lipopolysaccharide-induced interleukin-6 production is controlled by glycogen synthase kinase-3 and STAT3 in the brain. J Neuroinflammation 6: 9, 2009.
129. Cheng YL, Wang CY, Huang WC, et al: Staphylococcus aureus induces microglial inflammation via a glycogen synthase kinase 3beta-regulated pathway. Infect Immun 77: 4002-4008, 2009.
130. Wang MJ, Huang HY, Chen WF, Chang HF and Kuo JS: Glycogen synthase kinase-3beta inactivation inhibits tumor necrosis factor-alpha production in microglia by modulating nuclear factor kappaB and MLK3/JNK signaling cascades. J Neuroinflammation 7: 99, 2010.
131. Colasanti M, Persichini T, Di Pucchio T, Gremo F and Lauro GM: Human ramified microglial cells produce nitric oxide upon Escherichia coli lipopolysaccharide and tumor necrosis factor alpha stimulation. Neurosci Lett 200: 144-146, 1995.
132. Block ML and Hong JS: Chronic microglial activation and progressive dopaminergic neurotoxicity. Biochem Soc Trans 35: 1127-1132, 2007. (Pubitemid 350206444)
133. Członkowska A, Kohutnicka M, Kurkowska-Jastrzebska I and Członkowski A: Microglial reaction in MPTP (1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine) induced Parkinson's disease mice model. Neurodegeneration 5: 137-143, 1996.
134. Przedborski S and Vila M: The 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine mouse model: a tool to explore the pathogenesis of Parkinson's disease. Ann NY Acad Sci 991: 189-198, 2003. (Pubitemid 36793814)
135. Duka T, Duka V, Joyce JN and Sidhu A: Alpha-Synuclein contributes to GSK-3beta-catalyzed Tau phosphorylation in Parkinson's disease models. FASEB J 23: 2820-2830, 2009.
136. Watcharasit P, Thiantanawat A and Satayavivad J: GSK3 promotes arsenite-induced apoptosis via facilitation of mitochondria disruption. J Appl Toxicol 28: 466-474, 2008. (Pubitemid 351716531)
137. Cookson MR: The biochemistry of Parkinson's disease. Annu Rev Biochem 74: 29-52, 2005.